CONTEXT

AIDS (Acquired Immune Deficiency Syndrom) pandemic is responsible of the death of an estimated 2,1 million people in 2007, inculing 330 000 children. In the same year, an estimated 33,2 million people worldwide lived with the HIV virus.

At present, tritherapies including nucleosidic inhibitors (INTI like zidovudine (AZT)), non nucleosidic inhibitors (INNTI) and/or antiproteases (IP) allowed a notable decrease of the mortality caused by HIV virus’ infections. However, genotypes showing resistance against an antiviral are found in 80% of patients, and more worrying, 45,5% of viral populations are resistant to an association INTI/IP and 26% to an association of the three anti-VIH classes. Moreover, some side effects (lipoatrophies, lipodystrophies, hypertriglycidemy etc) appeared in 70% of patients.

In this situation, it is necessary to explore other steps of HIV replicative cycle in order  to develop an efficient treatment of AIDS.